Deal · licensing
Eli Lilly and Company / Chugai Pharmaceutical Co., Ltd.
Announced Sep 10, 2018 · closed
Deal terms
- Parties
- Eli Lilly and Company · Chugai Pharmaceutical Co., Ltd.
- Deal type
- licensing
- Territory
- Global
- Closing date
- Sep 10, 2018
- Upfront
- Not disclosed
- Milestones
- Not disclosed
- Royalties
- Tiered royalties on net sales
- Equity terms
- None disclosed
- Headline value
- Not disclosed (contingent on milestones)
Assets
View all →Sources
- registryprimary record
SURPASS-2: Tirzepatide versus semaglutide in type 2 diabetes
Eli Lilly and Company · ClinicalTrials.gov · May 17, 2019 · NCT03954834